Haloperidol versus placebo for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Irving, Claire B ^a   Adams, Clive E ^a   Lawrie, Stephen ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Antipsychotic agents *therapeutic use ; Haloperidol *therapeutic use ; Humans; Placebo effect; Randomized controlled trials as topic; Schizophrenia *drug therapy

Indexed keywords

HALOPERIDOL; PLACEBO;

AKATHISIA; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE SEVERITY; DRUG EFFICACY; DYSTONIA; FOLLOW UP; HUMAN; MOTOR DYSFUNCTION; PARKINSONISM; RELAPSE; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE;

EID: 77950177889     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003082.pub2     Document Type: Review

References (207)

1. Arvanitis 1997 {published data only} Arvanitis LA, Miller BG. (ICI 204,636): An atypical antipsychotic: Results from a multiple fixed dose, placebo-controlled study. Proceedings of XXth Collegium Internationale Neuro-Psychopharmacologicum. June 23-27th; Melbourne, Australia. 1996.
2. Arvanitis LA, Miller BG. Quetiapine, an atypical antipsychotic -results from a multiple fixed dose, placebo-controlled study. Proceedings of 149th Annual Meeting American Psychiatric Association. May 4-9th. 1996.
3. Arvanitis LA, Miller BG, Kowalcyk BB. Efficacy of 'Seroquel' (Quetiapine Fumarate) in affective symptoms of schizophrenia). Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8-12th; Waikoloa, Hawai, USA. 1997.
4. * Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry 1997;42:233-46.
5. Borison RL, Arvanitis LA, Miller BG. A comparison of five fixed doese of 'Seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia. Proceedings of 8th Biennial Winter Workshop on Schizophrenia. March 16-22nd; Crans Montana, Switzerland. 1996.
6. Borison RL, Arvantis LA, Miller BG. A multiple fixed-dose, placebo-controlled trial with 'Seroquel' - An atypical antipsychotic. Biological Psychiatry 1996;39:333.
7. Cantillon M. [Quetiapine fumarate reduces aggression]. Proceedings of the 11th Annual Meeting of the American Association of Geriatric Psychiatry; San Diego, California, USA. 1997.
8. Cantillon M, Arvanitis LA, Miller BG, Kowalcyk. 'Seroquel' (Quetiapine Fumarate) reduces hositility and aggression in patients with acute schizophrenia. Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8-12th; Waikoloa, Hawai, USA. 1997.
9. Cantillon M, Goldstein JM. Efficacy of Quetiapine fumarate in affective symptoms of schizophrenia. Proceedings of American Psychiatric Association Annual Meeting. May 30th-June 4th; Toronto, Ontario, Canada. 1998.
10. Hellewell JSE, Cameron-Hands D, Cantillon M. Seroquel: Evidence for efficacy in the treatment of hostility and aggression. 9th Biennial Winter Workshop on Schizophrenia. February 7-13th; Davos, Switzerland. 1998.
11. Hong W, Arvanitis L. Reduction of the positive symptoms of schizophrenia by (ICI 204,636): Results from phase II and III clinical trials. Proceedings of 9th European College of Neuropsychopharmacology Congress. September 21-25th; Amsterdam, The Netherlands. 1996.
12. Hong WW, Arvanitis L. The atypical profile of (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. Proceedings of the 9th European College of Neuropsychopharmacology Congress. September 21-25th; Amsterdam, The Netherlands. 1996.
13. Hong WW, Arvanitis LA, Miller BG. (ICI 204,636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin. Proceedings of the XXth Collegium Internationale Neuropsychopharmacologicum. June 23-27th; Melbourne, Australia. 1996.
14. Hong WW, Arvanitis LA, Miller BG. Quetiapine does not differ from placebo in the incidence of extrapyramidal syndrome of effect on plasma prolactin. Proceedings of the 149th Annual Meeting American Psychiatric Association. May 4-9th. 1996.
15. Beasley 1996 {unpublished data only} Beasley C, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM, Paul S. Acute and long-term results of the North American double-blind olanzapine trial. Proceedings of the 4th International Conference. October 6-9th; Vancouver BC, Canada. 1996.
16. * Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAD study group. Olanzapine versus placebo and haloperidol; Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
17. Beasley CM, Tollefson GD, Tran PV. Efficacy of Olanzapine: An overview of pivotal clinical trials. Journal of Clinical Psychiatry 1997;58:7-12.
18. Crawford AMK, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia research 1997;26:41-54.
19. Hamilton SH, Revicki DA, Genduso LA, Beasley CM. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998;18:41-9.
20. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine trial. Journal of Clinical Psychopharmacology 2001;21:14-20.
21. Revicki D, Genduso L. Effect of Olanzapine on deficit syndrome symptoms in chronic schizophrenia. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress; September 30th - October 4th; Venice, Italy. 1997.
22. Sanger T, Tollefson GD. A controlled study on the course of primary and secondary negative symptoms. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997.
23. Satterlee W, Beasley C, Sanger T, Tran P, Tollefson G. Olanzapine, a new atypical antipsychotic. Proceedings of 5th International Congress on Schizophrenia Research. April 6-12th; Wormsprings, USA. 1996.
24. Tollefson G. Update on new atypical antipsychotics. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th - October 4th; Venice, Italy. 1995.
25. Tollefson G, Beasley C, Tran P, Sanger T. Olanzapine: An exciting atypical antipsychotic. The clinical experience. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th - October 4th; Venice, Italy. 1995.
26. Tollefson G, Sanger T, Beasley C. The course of primary and secondary negative symptoms in a placebo-and comparatorcontrolled trial of the typical antipsychotic olanzapine. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21-25th; Amsterdam, The Netherlands. 1996.
27. Tollefson GD. Olanzapine: A novel antipsychotic with a broad spectrum profile. Proceedings of XIXth Collegium Internationale Neuro- psychopharmacologicum Congress. June 27th - July 1st; Washington DC, USA. 1994.
28. Tollefson GD. The value of atypical antipsychotic medications. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997.
29. Tollefson GD, Beasley CM, Tran PV, Sanger T. [The next generation of antipsychotics]. Proceedings of 148th Annual Meeting of the American Psychiatric Association. May 20-5th; Miami, USA. 1995.
30. Tollefson GD, Beasley CM, Tran PV, Sanger T. Olanzapine: A novel antipsychotic with a broad spectrum. Proceedings of 49th Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 18-22nd; Philadelphia, USA. 1994.
31. Tollefson GD, Sanger T, Beasley CM. The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of 149th American Psychiatric Association Annual Meeting. May 4-9th. 1996.
32. Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind, placebo and haloperidol controlled clinical trial with olanzapine. American Journal of Psychiatry 1997;154:466-74.
33. Tollefson GD, Sanger TM, Beasley CM. The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of XXth Collegium Internationale Neuropsychopharmacologicum. June 23-27th; Melbourne, Australia. 1996.
34. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry 1998;43:803-10.
35. Tollefson GD, Sanger TM, Beasley CM, Tran PV. Is there a relationship between EPSE and efficacy: faction or fiction. Proceedings of Campaign on Schizophrenia. March 10-12th; Florence, Italy. 1995.
36. Tran P, Beasley C, Tollefson G, Beuzen J, Dellva M, Sanger T, Paul S. Acute and long-term results of the North American double-blind Olanzapine trial. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress. September 30th - October 4th; Venice, Italy. 1995.
37. Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S, Van Ostrand R, Paul S. Acute and long term results of the North American double-blind olanzapine trial. Proceedings of 20th Collegium Internationale Neuropsychopharmacologicum Congress. June 23-27th; Melbourne, Australia. 1996.
38. Tran P, Dellva M, Rampey V, Tollefson G, Beasley C. Long-term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21-25th; Amsterdam, The Netherlands. 1996.
39. Tran PV, Beasley CM, Tollefson GD, Sanger T, Satterlee WG. Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Proceedings of XIXth Collegium Internationale Neuro-psychopharmacologicum Congress. June 27th - July 1st; Washington DC, USA. 1994.
40. Wood AJ, Beasley CM, Tollefson GD, Tran PV. [Efficacy of olanzapine in the post ive and negative symptoms of schizophrenia]. Proceedings of 7th Congress of the European College of Neuropsychopharmacology. October 16-21st; Jerusalem, Israel. 1994.
41. Bechelli 1983 {published data only} * Bechelli LPC, Ruffino-Netto A, Hetem G. A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research 1983;16:305-11.
42. Borison 1989 {published data only} * Borison RL, Sinah D, Haverstock S, McLarnon MC, Diamond B. Efficacy and safety of tiospirone vs haloperidol and thioridazine in a double-blind, placebo-controlled trial. Psychopharmacology Bulletin 1989;25:190-3.
43. Borison 1992a {published data only} Borison R, Pathiraga A, Diamond B, Meibach R. Risperidone and Schizophrenia. Proceedings of 5th World Congress of Biological Psychiatry. June 9-14th; Florence, Italy. 1991.
44. Borison RL, Diamond BI, Augusta GA. Serotonin modulation of dopaminergic-medicated extrapyramidal side effects. Proceedings of 43rd Annual Meeting of the American Academy of Neurology. April 21-27th; Boston, USA. 1991.
45. Borison RL, Diamond BI, Pathiraja A, Meibach RC. Clinical profile of risperidone in chronic schizophrenia. Proceedings of 17th Congress of Collegium Internationale Neuropsychopharmacologicum. 1993.
46. * Borison RL, Pathiraja AP, Diamond B, Meibach RC. Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin 1992;28:213-8.
47. Chouinard 1993 {published data only} Chouinard G. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicentre risperidone study. Journal of Clinical Psychopharmacology 1995;15:S36-44.
48. Chouinard G, Albright P. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology 1997;17:298-307.
49. Chouinard G, Arnott W. The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Proceedings 47th Annual Convention and Scientific Program of the Society of Biological Psychiatry. April 29th - May 3rd; Washington DC, USA. 1992.
50. * Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian Multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology 1993;13:25-40.
51. Chouinard G, Vainer JL, Beauclair L. Dose regimens of neuroleptics in negative symptoms. Proceedings of 19th Collegium Internationale Neuro-Psychopharmacologicum Congress. June 27th - July 1st; Washington DC, USA. 1994.
52. Chouindard G, Arnott W. Antidyskinetic effect of risperidone in chronic schizophrenic patients. Proceedings of 18th Collegium Internationale Neuro-Psychopharmacologicum Congress. June 28th - July 2nd; Nice, France. 1992.
53. Durost 1964 {published data only} * Durost H, Lee H, Arthurs D. An early evaluation of Haloperidol. The Butyrophenones in Psychiatry. Edited by HE Lehmann and TA Ban. Channel Press Inc, 1964:70-3.
54. Garry 1962 {published data only} * Garry JW, Leonard TJ. Haloperidol: A controlled trial in chronic schizophrenia. British Journal of Psychiatry 1962;108:105-7.
55. Howard 1974 {published data only} * Howard J. Haloperidol for chronically hospitalised psychotics: A double-blind comparison with thiothixene and placebo; a follow-up open evaluation. Diseases of the Nervous System 1974;35:458-63.
56. Jann 1997 {published data only} * Jann MW, Crabtree BL, Pitts WM, Francis Lam YW, Carter JG. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology 1997;36:32-6.
57. Kane 2002 {published data only} Anutosh S, Ali MW, Ingenito G, Carson WH. Controlled study of aripiprazole and haloperidol in schizophrenia. 11th Association of European Psychiatrists Congress. May 4-8, Stockholm, Sweden. 2002.
58. Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 13th Congress of the European College of Neuropsychopharmacology [CD-ROM]: Conifer Excerpta Medica Medical Communications BV. P2075. 2000.
59. Daniel D, Stock E, Wilber C, Marcus R, Carson Jr WH, Manos G, Iwamoto T. Intramuscular Aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association. May 1-6; New York, USA. 2004.
60. * Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and Safety of Aripiprazole and Haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 2002;63:763-71.
61. Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychoitc disorders: comparison with haloperidol and placebo. 153rd Annual Meeting of the American Psychiatric Association. May 13-8; Chicago, USA. 2000.
62. Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association. May 18-23; Philadelphia, PA, USA. 2002.
63. Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Abstracts of the XII CINP Congress, Brussels, Belgium, July 9-13. 2000.
64. Klieser 1989 {published data only} * Klieser E, Lehmann E. Experimental examination of trazodone. Clinical Neuropharmacology 1989;12:S18-24.
65. Marder 1994 {published data only} * Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994;151:825-35.
66. Nishikawa 1982 {published data only} * Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology 1982;77:301-4.
67. Nishikawa 1984 {published data only} * Nishikawa T, Tsuda A, Tanaka M, Hoaki Y, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of haloperidol and propericiazine. Psychopharmacology 1984;82:153-6.
68. Reschke 1974 {published data only} * Reschke RW. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Diseases of the Nervous System 1974;35:112-5.
69. Selman 1976 {published data only} * Selman FB, McClure RF, Helwig H. Loxapine succinate: A double-blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research 1976;19:645-52.
70. Selman FB, McClure RF, Helwig H. Loxapine succinate: essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues. Psychololgie Medicale 1979;11:1533-40.
71. Serafetinides 1972 {published data only} * Sefafetinides EA,Willis D, Clark ML. Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: II The electroencephalographic effects of chemically unrelated antipsychotics. The Journal of Nervous and Mental Disease 1972;155:366-9.
72. Serafentinides EA. Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry 1973;8:214-6.
73. Serafetinides EA. Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System 1973;34:190-1.
74. Serafetinides EA, Clark ML. Psychological effects of single dose antipsychotic medication. Biological Psychiatry 1973;7:263-7.
75. Serafetinides EA, Collins S, Clark ML. Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: Chemically unrelated antipsychotics as therapeutic alternatives. The Journal of Nervous and Mental Disease 1972;154:31-42.
76. Simpson 1967 {published data only} * Simpson GM, Angus JWS, Edwards JG. A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research 1967;9:407-12.
77. Spencer 1992 {published data only} Spencer E, Alpert M, Pouget E. Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacology Bulletin 1994;30:199-202.
78. Spencer EK, Alpert M, Pouget ER. [Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1-4th; Boca Raton, USA. 1993.
79. * Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR, Campbell M. Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin 1992;28:183-6.
80. Vichaiya 1971 {published data only} * Vichaiya V. Clinical trial of haloperidol in schizophrenia. Journal of Psychiatric Association of Thailand 1971;16(1):31-43.
81. Alpert 1995 {published data only} * Alpert M, Pouget ER, Sison C, Yahia M, Allan E. Clinical and Acoustic Measures of the Negative Syndrome. Psychopharmacology Bulletin 1995;31:312-26.
82. Alphs 1993 {published data only} * Alphs LD. [Response of negative symptom subtypes to remoxipride]. Proceedings of 146th American Psychiatric Association Annual Meeting. May 22-27th; San Francisco, USA. 1993.
83. Arvanitis 2002 {published data only} * Arvanitis L, Bauer D, Rein W. Results of the metatrial project: efficacy and tolerability of four novel compounds in schizophrenia and schizoaffective disorder. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum) 2002;5:S188.
84. Rein W, Arvanitis L. Antipsychotic effect of four different compounds - results of the metatrial. Journal of the European College of Neuropsychopharmacology 2003;13:S95.
85. Augustin 1996 {published data only} * Augustin BG, Jann MW, Crabtree BL, Pitts WM, Carter JG. Plasma alpha-one acid glycoprotein (AAG) and haloperidol (H) concentrations in schizophrenic patients. Proceedings of XXth Collegium Internationale Neuropsychopharmacologicum. June 23-27th; Melbourne, Australia. 1996.
86. Azima 1960 {published data only} * Azima H, Durost H, Arthurs D. The effect of R-1625 (Haloperidol) in mental syndromes: A multiblind study. American Journal of Psychiatry 1960;117:546-7.
87. Ban 1969 {published data only} * Ban TA. Treatment of acute and chronic psychoses with haloperidol: review of clinical results. Current Therapeutic Research 1969;11(5):284-8.
88. Bateman 1979 {published data only} * Bateman DN, Dutta DK, McCelland HA, Rawlins MD. Metoclopramide and haloperidol in tardive dyskinesia. British Journal of Psychiatry 1979;135:505-8.
89. Ben-dor 1998 {published data only} * Ben-dor A, Gelkoph M. Vitamin E: An alternative to anticholinergic drugs?. Proceedings of 9th Congress of the Association of European Psychiatrists. September 20-24th; Copenhagen, Denmark. 1998.
90. Beuzen 1996 {published data only} * Beuzen JN, Taylor N, Wesnes K, Wood A. Olanzapine - cognitive and motor effects in healthy elderly. Proceedings of Xth World Congress of Psychiatry. August 23-28th; Madrid, Spain. 1996.
91. Blum 1969 {published data only} Blum RA, Livingston PB, Shader RI. Changes in cognition, attention and language in acute schizophrenia. Diseases of the Nervous System 1969;30:31-6.
92. Brandrup 1961 {published data only} * Brandrup E, Kristjansen P. A controlled clinical test of a new psycholeptic drug (Haloperidol). British Journal of Psychiatry 1961;107:778-82.
93. Browne 1988 {published data only} * Browne FWA, Cooper SJ, Wilson R, King DJ. Serum haloperidol levels and clinical response in chronic, treatment resistant schizophrenic patients. Journal of Psychopharmacology 1988;2:94-103.
94. Buchsbaum 1992 {published data only} * Buchsbaum MS, Potkin SG, Siegel Jr BV, Lohr J, Katz M, Gottschalk LA, Gulasekaram B, Marshll JF, Lottenberg S, Teng CY, Plon L, Bunney WF. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Archives of General Psychiatry 1992;49:966-74.
95. Caroli 1975 {published data only} * Caroli F, Littre-Poirier MF, Ginestet D, Deniker P. Essai d'interruption des antiparkinsoniens dans les traitements neruoleptiques au long cours. L'Encephale 1975;1:69-74.
96. Cho-Boon 1989 {published data only} * Cho-Boon S, Ying-Chiao L, Jeng-Ping H. [Haloperidol for schizophrenic inpatients with dosage regimens]. Proceedings of 8th World Congress of Psychiatry. October 12-19th; Athens, Greece. 1989.
97. Contreas 1988 {published data only} * Contreas SA, Maas JW, Seleshi E, Bowden CL. Urine and plasma levels of dopamine metabolites in response to apomorphine and neuroleptics in schizophrenics. Biological Psychiatry 1988;24:815-8.
98. Craft 1965 {published data only} * Craft M. A trial of haloperidol in schizophrenia. Clinical Trials Journal 1965;3:140-2.
99. Crow 1986 {published data only} * Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. II. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986;148:120-7.
100. Deberdt 1971 {published data only} * Deberdt R, Luyssaert W. Le traitement de psychoses dellrantes chroniques par la pipothiazine (19.366 RP) et l'ester palmitique de pipothiazine (19.55 RP). Proceedings of Vth World Congress of Psychiatry. November 28th - December 4th; Cuidad de Mexico, Mexico. 1971.
101. Diamond 1991 {published data only} Diamond BI, O'Neal E,Wang J, Borison RL. [Plasma homovanillic acid in schizophrenia]. Proceedings of 5th World Congress of Biological Psychiatry. June 9-14th; Florence, Italy. 1991.
102. * Diamond BI, O'Neal E, Wang J, Borison RL. [Plasma homovanillic acid and drug response in schizophrenia]. Proceedings of III International Congress on Schizophrenia Research. April 21-25th; Tucson, USA. 1991.
103. Gelders 1986 {published data only} Gelders Y, Ceulemans D, Hoppenbrouwers ML, Reyntjens A, Mesotten F. [Ritanserin, a selective serotonin antagonist in chronic schizophrenia]. Proceedings of IVth World Congress of Biological Psychiatry. September 8-13th; Philadelphia, USA. 1985.
104. * Gelders Y, Vanden Bussche G, Reytjens A, Janssen P. Serotonin S2 receptor blockers in the treatment of chronic schizophrenia. Clinical Neuropharmacology 1986;9:325-7.
105. Glovinsky 1992 {published data only} * Glovinsky D, Kirch DG, Wyatt RJ. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biological Psychiatry 1992;31:968-70.
106. Huygens 1973 {published data only} * Huygens H, Vereecken JLTM, Tanghe A. Dexetimide (R 16 470) in the control of neuroleptic-induced extrapyramidal side-effects: Its prophylactic value and duration of action. Psychiatria Neurologia Neurochirurgia 1973;76:251-9.
107. Itil 1981 {published data only} * Itil TM, Shapiro D, Schneider SJ, Francis IB. Computerized EEG as a predictor of drug response in treatment resistant schizophrenics. The Journal of Nervous and Mental Disease 1981;169:629-37.
108. Jolley 1990 {published data only} * Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301:837-42.
109. Kasper 1996 {published data only} * Kapser S. Negative symptoms and Sertindole. 9th Congress of the European College of Neuropsychopharmacology. Sep21-25; Amsterdam, The Netherlands. 1996.
110. Wehnert A, Stilwell C, Mack R, Sloth-Nielsen M. Extrapyramidal symptoms and sertindole - analysis of three double-blind, haloperidol-referenced, phase III clinical trials. 10th European College of Neuropsychopharmacology Congress. Sep 13-17; Vienna, Austria. 1997.
111. Ko 1989 {published data only} * Ko GN, Korpi ER, Kirch DG. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. Journal of Clinical Psychopharmacology 1989;9:186-90.
112. Kramer 1989 {published data only} * Kramer MS, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Cavicchia S, Little P, Schmidt R, Kimes I. Antidepressants in 'depressed' schizophrenic inpatients. Archives of General Psychiatry 1989;46:922-7.
113. Kramer MS, Voger WH, DiJohnson C, Sheves P, Cavicchia S, Litle P. Antidepressants in depressed schizophrenics. Proceedings of 141st American Psychiatric Association Annual Meeting. May 7-12th; Quebec, Canada. 1998.
114. Kurland 1981 {published data only} * Kurland AA, Nagaraju A. Viloxazine and the depressed schizophrenic - Methodological issues. Journal of Clinical Pharmacology 1981;21:37-41.
115. Labarca 1993 {published data only} * Labarca R, Silva H, Jerez S, Ruiz, A, Forray MI, Gysling K, Andres ME, Bustos G, Castillo Y, Hono J. Differential effects of haloperidol on negative symptoms in drug naive schizophrenic patients: effects on plasma homovanillic acid. Schizophrenia Research 1993;9:29-34.
116. Lee 1968 {published data only} * Lee H. Use of haloperidol in a "hard-core" chronic schizophrenic population. Psychosomatics 1968;9:267-71.
117. Lehmann 1967 {published data only} * Lehmann HE, Ban TA, Lee H. The effectiveness of combined phenothiazine and butyrophenone treatment in chronic schizophrenic patients. Current Therapeutic Research 1967;9:36-7.
118. Lemmer 1993 {published data only} Lemmer W, Klieser E, Klimke A. Experimental comparison of the efficacy of the dopamine autoreceptor agonist pramipexole versus haloperidol and placebo in acute schizophrenia. Pharmacopsychiatry 1993;26:102.
119. Lindborg 2003 {published data only} Lindborg SR, Beasley CM, Alaka K, Taylor CC. Effects of intramuscular olanzapine vs haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Research 2003;119:113-23.
120. Magelund 1979 {published data only} * Magelund G, Gerlach J, Casey DE. Neuroleptic-potentiating effect of alpha-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial. Acta Psychiatrica Scandivica 1979;60:185-9.
121. Malaspina 1997 {published data only} * Malaspina D, Johnson J, Bruder G, Gorman J, Kaufmann C, Amador X, Goetz R. [Brain laterality and haloperidol response in schizophrenia]. Proceedings of 52nd Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 14-18th; San Diego, USA. 1997.
122. Nagaraja 1977 {published data only} * Nagaraja J. Clinical use of haloperidol (Serenace) in child psychiatry. Child Psychiatry Quarterly 1977;10:14-20.
123. Necomer 1992 {published data only} * Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease. Psychopharmacology Bulletin 1992;28:101-7.
124. Nguyen 1984 {published data only} * Nguyen J, Tamminga C, Alphs L, Stolk J, Heinrichs D, Carpenter WT. Acute and steady state kinetics of haloperidol in schizophrenia. Journal of Clinical Pharmacology 1984;24:339.
125. Nth America 1997 {published data only} Anderson C, True J, Ereshefsky L, Miller A. [Risperidone. Clinical efficacy: role of the metabolite 9-hydroxy-risperidone]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1-4th; Boca Raton, USA. 1993.
126. Anderson CB, True J, Miller AL, Peters B, Velligan DI. [Risperidone dose, plasma levels and response]. Proceedings of 146th Annual Meeting of the American Psychiatric Association. May 22-27th; San Fransico, USA. 1993.
127. Lindenmayer JP. [Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia]. Proceedings of 146th Meeting of the American Psychiatric Association. May 22-27th; San Fransico, USA. 1993.
128. Marder SR. [Risperidone: Clinical development: North American Results]. Proceedings of 18th Collegium Internationale Neuropsychopharmacologicum Congress; June 28th - July 2nd; Nice, France. 1992.
129. Marder SR. [Risperidone: efficacy on positive and negative symptoms]. Proceedings of 1st International Risperidone Investigators Meeting; March 9-10th; Paris, France. 1992.
130. Marder SR. [Risperidone: Efficacy]. Proceedings of a roundtable meeting: Update on Serotonin/Dopamine Antagonists in Psychiatry; January 7th; New Orleans, USA. 1994.
131. Marder SR. Risperidone: Clinical development: North American Results. Clinical Neuropharmacology 1992;15(1):S92-3.
132. Marder SR, Chouinard G, Davis JM. [The clinical actions of risperidone]. Proceedings of 10th Congress of the European College of Neuropsychopharmacology; September 13-17th; Vienna, Austria. 1997.
133. Marder SR, Chouinard G, Davis JM. [The clinical actions of risperidone]. Proceedings of 35th Annual Meeting of the American College of Neuropsychopharmacology; December 9-13th; San Juan, Puerto Rico. 1996.
134. Marder SR, Chouinard G, Davis JM. [The clinical actions of risperidone]. Proceedings of 6th World Congress of Biological Psychiatry; June 22-27th; Nice, France. 1997.
135. * Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry 1997;58:538-46.
136. McEvoy JP. Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry 1994;55(5):S18-21.
137. Meibach RC, Risperidone Study Group. [A fixed-dose, parallel group study of risperidone vs haloperidol vs placebo]. Proceedings of 4th International Congress on Schizophrenia Research; April 17-21st; Colorado Springs, USA. 1993.
138. Moller HJ. [Incidence of EPS under risperidone therapy]. Proceedings of 1st International Risperidone Investigators Meeting; March 9-10th; Paris, France. 1992.
139. Schooler NR. [Negative symptoms, risperidone and dose]. Proceedings of 146th American Psychiatric Association Annual Meeting; May 22-27th; San Fransico, USA. 1993.
140. Schooler NR. Negative symptoms in schizophrenia:assessment of the effect of risperidone. Journal of Clinical Psychiatry 1994;55(5):S22-8.
141. Simpson GM, Lindenmayer JP. Extrapyramidal Symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology 1997;17:194-201.
142. Okasha 1964 {published data only} * Okasha A, Tewfik GI. Haloperidol: A controlled clinical trial in chronic disturbed psychotic patients. British Journal of Psychiatry 1964;110:56-60.
143. Ortega-Soto 1994 {published data only} * Ortega-Soto HA, Brunner E, Apiquian R, de la Torre P. [Therapeutic minimum dose of haloperidol (HLP) in schizophrenia]. Proceedings of XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress; June 27th - July 1st; Washington DC, USA. 1994.
144. Ota 1973 {published data only} * Ota KY, Kurland AA. A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia. The Journal of Clinical Pharmacology 1973;13:99-110.
145. Pathiraja 1995 {published data only} * Pathiraja AP, Diamond BI, Borison RL, Meibach RC, Anand R. [Relationship between creatine phosphokinase, psychotic symptoms and novel antipsychotic drugs]. Proceedings of 5th International Congress on Schizophrenia Research; April 6-12th; Wormsprings, USA. 1995.
146. Pool 1976 {published data only} * Pool D, Bloom W, Mielker DH, Roniger JJ, Gallant DM. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Current Therapeutic Research 1976;19:99-104.
147. Potkin 1984 {published data only} * Potkin SG, Shen YC, Pardes H, Zhou DF, Phelps B, Shu L, Poland R. [Failure of insulin coma and presence of a therapeutic window for haloperidol in chinese schizophrenics]. Proceedings of 14th (CINP) Collegium Internationale Neuro-Psychopharmacologicum Congress; June 19-23rd; Florence, Italy. 1984.
148. Potkin 1995 {published data only} Potkin S, Wu J, Anand R, Bear R, Carreon D, Hartman R, Keator D. Neuroimaging to evaluate atypical antipsychotic compounds: An FDG PET study of SDZ MAR 327. Proceedings of XXth Collegium Internationale Neuro-Psychopharmacologicum; June 23-27th; Melbourne, Australia. 1996.
149. * Potkin S, Wu J, Fallon F, Anand R, Hartman R, Bear R, Carreon D, Telford J, Plon L, Keator D. Functional Neuroimaging to evaluate atypical antipsychotic compounds: An FDG PET study of SDZ MAR 327. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress; September 30th - October 4th; Venice, Italy. 1995.
150. Potkin 2000 {published data only} Potkin SG, Basile VS, Badri F, Keator D, Wu JC, Alva G, Doo M, Bunney Jr WE, Kennedy JL. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. International Journal of Neuropsychopharmacology 2000;3:S6.
151. Price 1985 {published data only} * Price W, Giannini AJ, Loiselle R. [Antischizophrenia effects of verapamil]. Proceedings of IVth World Congress of Biological Psychiatry; September 8-13th; Philadelphia, USA. 1985.
152. Price 1987 {published data only} * Price WA. Antipsychotic effects of Verapamil in schizophrenia. Hillside Journal of Clinical Psychiatry 1987;9:225-30.
153. Rees 1965 {published data only} * Rees L, Davies B. A study of the value of haloperidol in the management and treatment of schizophrenic and manic patients. International Journal of Neuropsychiatry 1965;1(3):263-6.
154. Roitman 1989 {published data only} * Rothman G, Levine J, Bermudas Y, Bel maker RH. An adenylate cyclase inhibitor in the treatment of excited psychosis. Human Psychopharmacology 1998;13:121-5.
155. Ruskin 1991 {published data only} * Ruskin PE, Nyman G. Discontinuation of neuroleptic medication in older, outpatient schizophrenics: A placebo-controlled, double-blind trial. The Journal of Nervous and Mental Disease 1991;179:212-5.
156. Samuels 1961 {published data only} * Samuels S. A controlled study of haloperidol: the effects of small dosages. Clinical Notes 1961;118:253-4.
157. Singh 1972 {published data only} * Singh MM, Discipo WJ. Changes in staff anxiety and attitudes during a double blind study of haloperidol in acute schizophrenics within a structured milieu. The Journal of Nervous and Mental Disease 1972;155(4):245-56.
158. Soloff 1986 {published data only} * Soloff PH, George A, Swami NR, Schulz P, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders: a doubleblind study of amitriptyline, haloperidol, and placebo. Pharmacotherapy 1986;43:691-7.
159. Stankovska 2002 {published data only} * Stankovska GN. The effects of risperidone in the treatment of schizophrenia. XIIth World Congress of Psychiatry; Aug 24-9; Yokohama, Japan. 2002.
160. Taverna 1972 {published data only} * Taverna P, Ghisoni T, Poggi E. Etude controlee de l'activite antipsychotique du dogmatil. Psychologie Medicale 1972;4:811-8.
161. Teja 1975 {published data only} * Teja JS, Grey WH, Clum JM, Warren C. Tranquilzers or anti-depressants for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry 1975;9:241-7.
162. Van Lommel 1974 {published data only} * Van Lommel R, Baro F, Dom R. The influence of haloperidol and penfluridol on the learning capacity of the schizophrenic. Arzneimittelforschung 1974;24:1072- 4.
163. Volavka 1992 {published data only} Czobor P, Volavka J. Dimensions of the Brief Psychiatric Rating Scale: An examination of stability during haloperidol treatment. Comprehensive Psychiatry 1996;37:201-15.
164. Czobor P, Volavka J. Positive and negative symptoms: Is their change related?. Schizophrenia Bulletin 1996;22:577-90.
165. * Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanga P, Krakowski M, Chan JC, Crowner M, et al.Haloperidol blood levels and clinical effects. Archives of General Psychiatry 1992;49:354-61.
166. Zimbroff 1997 {published data only} Baker R, Mack R, Morris D, Sebree T, Kashkin K. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Proceedings of 9th ENCP (European College of Neuropsychopharmacology) Congress; September 21-25th; Amsterdam, The Netherlands. 1996.
167. Bera RB, Potkin SG. [Brain imaging to determine the effects of sertindole in schizophrenic patients]. Proceedings of 4th International Conference Schizophrenia: Breaking down the Barriers; October 6-9th; Vancouver BC, Canada. 1996.
168. Daniel D, Targum S, Zimbroff D, Mack R, Zborowski J, Morris D, Sebree T,Wallin B. Efficacy, safety, and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients. Proceedings of 34th Annual Meeting of the American College of Neuropsychopharmacology; December 11-15th; San Juan, Puerto Rico. 1995.
169. Glick ID, Ramirez L, McCarthy BG, Kohlbeck P. [Extrapyramidal symptom profile of sertindole]. Proceedings of 53rd Annual Convention and Scientific Program of the Society of Biological Psychiatry; May 27-31st; Toronto, Canada. 1998.
170. Larson GK, Mack RJ, Zborowski J, Morris DD, Sebree TB, Wallin BA. Three doses each of sertindole and haloperidol in schizophrenics. Proceedings of Xth World Congress of Psychiatry; August 23-28th; Madrid, Spain. 1996.
171. Mack R, Zborowski J, Morris D, Sebree T, Wallin B. [Efficacy, safety and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients]. Proceedings of 34th Annual Meeting of the American College of Neuropsychopharmacology; December 11-15th; San Juan, Puerto -Rico. 1995.
172. Potkin SG, Zborowski J, Joseph N, Wu C, Mack RJ, Sebree TB, Wallin BA. [Brain Imaging to determine the effects of sertindole in schizophrenic patients]. Proceedings of 149th Annual Meeting American Psychiatric Association; May 4-9th. 1996.
173. Schulz SC, Mack R, Zborowski J, Morris D, Sebree T, Wallin B. [Efficacy, safety and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients]. Proceedings of 8th Biennial Winter Workshop on Schizophrenia, Crans Montana; March 16-22nd; Switzerland. 1996.
174. Tamminga C, Mack RJ, Zborowski JG, Morris D, Sebree B. Efficacy and safety of three doses of sertindole and haldol in schizophrenic patients. Proceedings of XXth Collegium Internationale Neuro-Psychopharmacologicum; June 23-27th; Melbourne, Australia. 1996.
175. Tamminga CA, Mack RA, Granneman GR, Silber CJ, Kashkin KB. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. International Clinical Psychopharmacology 1997;12:S29-35.
176. Targum S, Zborowski J, Schmitz HM, Sebree T, Wallin B. [Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients]. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress; September 30th - October 4th; Venice, Italy. 1995.
177. Zimbroff D, Mack RJ, Zborowski JG, Morris DD. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Proceeding of 149th American Psychiatric Association Annual Meeting; May 4-9th. 1996.
178. * Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry 1997;154(6):782-91.
179. Cucchaiaro 2001 {published data only}
180. Madalena 1967 {published data only}
181. George 2000 {published data only} A double-blind randomised comparison of the efficacacy and safety of short acting intramuscular olanzapine, short acting intramuscular haloperidol and intramuscular placebo in patients with schizophrenia. Ongoing study 2000.
182. Paykel 2000 {published data only} Prophylaxis of puerperal psychosis. Ongoing study 2000.
183. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
184. Awad 1997 Awad GA, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmaco Economics 1997;11:32-47.
185. Ayd 1972 Ayd FJ. Haloperidol: fifteen years of clinical experience. Diseases of the Nervous System 1972;33:459-69.
186. Ayd 1978 Ayd FJ. Haloperidol: twenty years' clinical experience. Journal of Clinical Psychiatry 1978;39:807-14.
187. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276(8):637-9.
188. Bland 1997 Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
189. Carpenter 1994 Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
190. Dally 1967 Dally P. Chemotherapy of Psychiatric Disorders. Logo Press Limited 1967.
191. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
192. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
193. Gulliford 1999 Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
194. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
195. Higgins 2005 Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons Ltd, 2005, issue 4.2.5.
196. Jablensky 1992 Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine Monograph Supplement 1992;20:1-97.
197. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
198. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
199. Quraishi 1999 Quraishi S, David A. Depot haloperidol decanoate for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001361]
200. Settle 1983 Settle EC, Ayd FJ. Haloperidol: a quarter century of experience. Journal of Clinical Psychiatry 1983;44:440-8.
201. Thornley 1998a Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317:1181-4.
202. Thornley 1998b Thornley B, Adams CE, Awad G. Chlorpromazine versus placebo for those with schizophrenia. Cochrane Database of Systematic Reviews 1998, Issue 4. [DOI: 10.1002/14651858.CD000284.pub2]
203. Thornley 2001 Thornley B, Adams CE, Awad G. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD000284.pub2]
204. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
205. Waddington 1997 Waddington JL, Scully PJ, O'Callaghan E. The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophrenia Research 1997;28:207-22.
206. Waraich 2001 Waraich P, Soares K, Marti J, Roque M. Haloperidol dose for exacerbation of schizophrenia. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD001951]
207. Willner 1997 Willner P. The dopamine hypothesis of schizophrenia: Current status, future prospects. International Clinical Psychopharmacology 1997;12:297-308.